Emerging roles of kisspeptin/galanin in age-related metabolic disease
Emerging roles of kisspeptin/galanin in age-related metabolic disease
复制标题
Kisspeptin/甘丙肽在年龄相关代谢疾病中的新作用
DOI：
10.1016/j.mad.2021.111571
复制
发表时间：
2021-09-16
影响因子：
5.3
通讯作者：
Shang, Wenbin
中科院分区：
文献类型：
--
作者：
Fang, Penghua;She, Yuqing;Shang, Wenbin
年龄是罹患肥胖和糖尿病等代谢疾病的主要危险因素。近几十年来，肥胖和 2 型糖尿病的发病率史无前例地增加。令人信服的是，大多数脑肠肽与发生代谢紊乱的较高风险相关，并且可能有助于年龄相关代谢疾病的病理生理学。不断积累的基础研究揭示了 Kisspeptin 和甘丙肽以不同方式参与改善胰岛素抵抗的有趣作用。在患有肥胖症和糖尿病的患者中，血浆吻肽素和甘丙肽水平发生了显着的、与性别相关的变化。 Kisspeptin 具有抑制食欲、预防肥胖的作用，其水平与肥胖和胰岛素抵抗呈负相关。虽然甘丙肽具有刺激食物摄入和体重的作用，但其水平与肥胖、HOMA-IR 和葡萄糖/甘油三酯浓度呈正相关。反过来，吻肽素和甘丙肽也显着增加葡萄糖的摄取和利用以及能量消耗。本文回顾了有关 Kisspeptin 和甘丙肽在年龄相关代谢疾病的病理生理学中的作用的最新证据。因此，应该考虑到，这些肽能信号传导的靶向调节可能有助于未来治疗与年龄相关的代谢疾病。
Age is a major risk factor for developing metabolic diseases such as obesity and diabetes. There is an unprecedented rise in obesity and type 2 diabetes in recent decades. A convincing majority of brain-gut peptides are associated with a higher risk to develop metabolic disorders, and may contribute to the pathophysiology of agerelated metabolic diseases. Accumulating basic studies revealed an intriguing role of kisspeptin and galanin involved in the amelioration of insulin resistance in different ways. In patients suffered from obesity and diabetes a significant, sex-related changes in the plasma kisspeptin and galanin levels occurred. Kisspeptin is anorexigenic to prevent obesity, its level is negatively correlative with obesity and insulin resistance. While galanin is appetitive to stimulate food intake and body weight, its level is positively correlative with obesity, HOMA-IR and glucose/triglyceride concentration. In turn, kisspeptin and galanin also distinctly increase glucose uptake and utilization as well as energy expenditure. This article reviews recent evidence dealing with the role of kisspeptin and galanin in the pathophysiology of age-related metabolic diseases. It should be therefore taken into account that the targeted modulation of those peptidergic signaling may be potentially helpful in the future treatment of age-related metabolic diseases.